Chemomab Therapeutics
CMMB
9 hedge funds and large institutions have $5.22M invested in Chemomab Therapeutics in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
68% more capital invested
Capital invested by funds: $3.11M → $5.22M (+$2.1M)
13% more funds holding
Funds holding: 8 → 9 (+1)
0.03% more ownership
Funds ownership: 0.02% → 0.05% (+0.03%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
+$2.01M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$1.96M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$348 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$74.4K |
| 2 |
RI
RTW Investments
New York
|
-$46.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.3K |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$6.26K |
| 5 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIH
1
Meitav Investment House
Bene-Beraq,
Israel
| $1.74M | +$1.96M | +5,645 | +1,384% |
|
|
PCM
2
Palisade Capital Management
Fort Lee,
New Jersey
| $1.66M | +$2.01M | +5,776 | New |
|
|
KCM
3
Kennedy Capital Management
St Louis,
Missouri
| $891K | -$6.26K | -18 | -0.6% |
|
|
AIC
4
AWM Investment Company
New York
| $448K | – | – | – |
|
|
RI
5
RTW Investments
New York
| $233K | -$46.3K | -133 | -14% |
|
|
6
Fidelity Investments
Boston,
Massachusetts
| $132K | -$74.4K | -214 | -32% |
|
|
DG
7
Delek Group
Herzliya,
Israel
| $114K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $6K | -$7.3K | -21 | -49% |
|
|
CCA
9
Catalyst Capital Advisors
Huntington,
New York
| – | -$3K | -8 | Closed |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | +$348 | +1 | New |
|
CMMB Hedge Fund Activity: Q2 2019 in Review
9 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q2 2019, worth a combined $5.22M — up 68% from $3.11M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CMMB positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Palisade Capital Management, opening a new position worth an estimated $2.01M. The largest seller was Fidelity Investments, cutting an estimated $74.4K.
- 9 institutional investors held Chemomab Therapeutics (CMMB) as of Q2 2019, up from 8 in Q1 2019.
- Funds reported $5.22M of Chemomab Therapeutics stock for Q2 2019, up 68% quarter-over-quarter.
- 2 funds opened new Chemomab Therapeutics positions in Q2 2019 and 1 closed out, a net change of +1 holder.
- The largest Chemomab Therapeutics buyer in Q2 2019 was Palisade Capital Management, an estimated $2.01M added.
- The largest Chemomab Therapeutics seller in Q2 2019 was Fidelity Investments, an estimated $74.4K sold.
Based on aggregated 13F filings for Q2 2019.